| 000 | 01663 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513202355.0 | ||
| 264 | 0 | _c20000317 | |
| 008 | 200003s 0 0 eng d | ||
| 022 | _a0031-6970 | ||
| 024 | 7 |
_a10.1007/s002280050005 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBroeders, M E | |
| 245 | 0 | 0 |
_aVerapamil causes decreased diaphragm endurance but no decrease of nocturnal O(2) saturation in patients with chronic obstructive pulmonary disease. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _cJan 2000 |
||
| 300 |
_a729-32 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBlood Gas Analysis |
| 650 | 0 | 4 |
_aCalcium Channel Blockers _xpharmacology |
| 650 | 0 | 4 |
_aCircadian Rhythm _xphysiology |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 |
_aDiaphragm _xdrug effects |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Diseases, Obstructive _xmetabolism |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMuscle Contraction _xdrug effects |
| 650 | 0 | 4 |
_aMuscle, Skeletal _xdrug effects |
| 650 | 0 | 4 |
_aOxygen _xmetabolism |
| 650 | 0 | 4 | _aPlacebos |
| 650 | 0 | 4 |
_aTheophylline _xpharmacology |
| 650 | 0 | 4 |
_aVasodilator Agents _xpharmacology |
| 650 | 0 | 4 |
_aVerapamil _xpharmacology |
| 700 | 1 | _aHeijdra, Y F | |
| 700 | 1 | _aSmits, P | |
| 700 | 1 | _aFolgering, H T | |
| 700 | 1 | _aKramers, C | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 55 _gno. 10 _gp. 729-32 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s002280050005 _zAvailable from publisher's website |
| 999 |
_c10618210 _d10618210 |
||